Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Non-Current Assets (2020 - 2025)

Ovid Therapeutics' Non-Current Assets history spans 6 years, with the latest figure at $76.6 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 111.35% year-over-year to $76.6 million; the TTM value through Dec 2025 reached $182.7 million, up 22.84%, while the annual FY2025 figure was $76.6 million, 111.35% up from the prior year.
  • Non-Current Assets reached $76.6 million in Q4 2025 per OVID's latest filing, up from $35.0 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $76.6 million in Q4 2025 to a low of $793980.0 in Q1 2021.
  • Average Non-Current Assets over 5 years is $27.8 million, with a median of $33.7 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: dropped 19.45% in 2021, then soared 2546.02% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $4.1 million in 2021, then soared by 487.49% to $23.9 million in 2022, then surged by 44.14% to $34.4 million in 2023, then grew by 5.22% to $36.2 million in 2024, then skyrocketed by 111.35% to $76.6 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Non-Current Assets are $76.6 million (Q4 2025), $35.0 million (Q3 2025), and $35.3 million (Q2 2025).